Freestone Grove Partners LP Biocryst Pharmaceuticals Inc Transaction History
Freestone Grove Partners LP
- $9.71 Trillion
- Q1 2025
A detailed history of Freestone Grove Partners LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Freestone Grove Partners LP holds 14,735 shares of BCRX stock, worth $163,705. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,735
Previous 30,313
51.39%
Holding current value
$163,705
Previous $228 Million
51.52%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
293Shares Held
177MCall Options Held
721KPut Options Held
489K-
Vanguard Group Inc Valley Forge, PA21.7MShares$241 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$222 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.93MShares$99.2 Million5.64% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.7MShares$96.7 Million1.06% of portfolio
-
State Street Corp Boston, MA7.81MShares$86.8 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $2.07B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...